Molecular therapy for glaucoma:  S-allylmercapto-N-acetylcysteine (ASSNAC) increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 3/April/2019, 12.06 am

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA AK027294 inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 2/April/2019, 6.50 am
April 2, 2019
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  PTPN14, SMARCA4, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 3/April/2019, 12.14 am
April 2, 2019
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General science” with an I.F of 34.661], by   Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for glaucoma:  S-allylmercapto-N-acetylcysteine (ASSNAC) increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, that  S-allylmercapto-N-acetylcysteine (ASSNAC), by increasing the expression of its target gene, it may increase the expression of Nmnat1. Thereby, it may: (1) increase NAD+ levels; (2) decrease Intraocular pressure; (3) improve pressure-induced damage; (4) increase insulin sensitivity; and (5) alleviate glaucoma (Fig.1). Thus,    S-allylmercapto-N-acetylcysteine (ASSNAC)  or its analogs either alone or in combination with other drugs, may be used to treat Glaucoma.

 

Figure 1. Mechanistic insights into how S-allylmercapto-N-acetylcysteine (ASSNAC) attenuates glaucoma. Fenofibrate, by increasing the expression of its target gene, enhances NAD+ levels and improves glaucoma

Figure 2. S-allylmercapto-N-acetylcysteine (ASSNAC)  functions as an anti-glaucoma agent by increasing NAD+ levels


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does S-allylmercapto-N-acetylcysteine (ASSNAC)  increase the levels of NAD+?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Molecular therapy for glaucoma:  S-allylmercapto-N-acetylcysteine (ASSNAC) increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 3/April/2019, 12.06 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.